Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Merola

Showing results (321-330 of 351) with videos related to

Pageof 36
Sort By:
Lancet (London, England)|December 9, 2022
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)Iain B McInnes, Akihiko Asahina, Laura C Coates, et al.
RMD Open|March 17, 2022
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studiesChristopher T Ritchlin, Philip J Mease, Wolf-Henning Boehncke, et al.
JACC. Cardiovascular Imaging|March 21, 2021
Impaired Coronary Vasodilator Reserve and Adverse Prognosis in Patients With Systemic Inflammatory DisordersBrittany N Weber, Emma Stevens, Lourdes M Perez-Chada, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 23, 2026
Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findingsRichard B Warren, Melinda Gooderham, Edward Lain, et al.
The Journal of Rheumatology|July 7, 2023
Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working GroupYing-Ying Leung, William Tillett, Maarten de Wit, et al.
JAMA Dermatology|May 15, 2026
Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical TrialMark Lebwohl, Andrew Blauvelt, Cynthia E Kartman, et al.
Dermatology (Basel, Switzerland)|September 19, 2021
International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual MeetingAlison H Kohn, Afsaneh Alavi, April W Armstrong, et al.
Journal of the American Academy of Dermatology|November 19, 2025
Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitorsAndrew Blauvelt, Bruce E Strober, Guy S Eakin, et al.
Dermatology and Therapy|January 13, 2022
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 TrialDiamant Thaçi, Bruce Strober, Kenneth B Gordon, et al.
The British Journal of Dermatology|August 28, 2025
SPECTREM Phase 3b Clinical Trial Results Through Week 16: Guselkumab Efficacy and Safety for the Treatment of Low Body Surface Area, Moderate Psoriasis With High-Impact Site InvolvementLinda Stein Gold, Alice B Gottlieb, April W Armstrong, et al.
Pageof 36

Showing results (321-330 of 351) with videos related to

Sort By:
Pageof 36
Lancet (London, England)|December 9, 2022
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)Iain B McInnes, Akihiko Asahina, Laura C Coates, et al.
RMD Open|March 17, 2022
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studiesChristopher T Ritchlin, Philip J Mease, Wolf-Henning Boehncke, et al.
JACC. Cardiovascular Imaging|March 21, 2021
Impaired Coronary Vasodilator Reserve and Adverse Prognosis in Patients With Systemic Inflammatory DisordersBrittany N Weber, Emma Stevens, Lourdes M Perez-Chada, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 23, 2026
Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findingsRichard B Warren, Melinda Gooderham, Edward Lain, et al.
The Journal of Rheumatology|July 7, 2023
Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working GroupYing-Ying Leung, William Tillett, Maarten de Wit, et al.
JAMA Dermatology|May 15, 2026
Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical TrialMark Lebwohl, Andrew Blauvelt, Cynthia E Kartman, et al.
Dermatology (Basel, Switzerland)|September 19, 2021
International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual MeetingAlison H Kohn, Afsaneh Alavi, April W Armstrong, et al.
Journal of the American Academy of Dermatology|November 19, 2025
Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitorsAndrew Blauvelt, Bruce E Strober, Guy S Eakin, et al.
Dermatology and Therapy|January 13, 2022
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 TrialDiamant Thaçi, Bruce Strober, Kenneth B Gordon, et al.
The British Journal of Dermatology|August 28, 2025
SPECTREM Phase 3b Clinical Trial Results Through Week 16: Guselkumab Efficacy and Safety for the Treatment of Low Body Surface Area, Moderate Psoriasis With High-Impact Site InvolvementLinda Stein Gold, Alice B Gottlieb, April W Armstrong, et al.
Pageof 36